Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
A major Novartis shareholder is demanding a board overhaul following a series of costly drug trial setbacks and strategic failures.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Novartis faced intense scrutiny following a triple asset stumble and the failure of its del-desiran late-stage DM1 study, which caused shares to fall and dragged down industry peers. In response to these costly deal and drug trial setbacks, a major shareholder called for a board shake-up and overhaul.
The headlines do not establish a definitive resolution regarding the board changes or future financial outcomes.
Epilogue added 61d ago, after coverage quieted.
The brief
Novartis is facing intense scrutiny from its investment community after a series of setbacks regarding its pharmaceutical assets. According to an exclusive report from Reuters, a major shareholder has called for a board shake-up, citing the financial and strategic impact of costly deal failures. This internal pressure coincides with the news that Del-desiran, a candidate drug, failed its late-stage DM1 study, a development that resulted in a drop in the company's share price as reported by Yahoo Finance. The company is currently grappling with these trial failures while investors shift their focus toward the organization's mergers and acquisitions strategy. Coverage from several industry-specific outlets emphasizes the broader impact of these events.
BioSpace reports that Novartis is dragging its peers down due to what it describes as a triple asset stumble. Fierce Pharma and FirstWord PHARMA have also highlighted the reports of the shareholder's demand for a board overhaul, focusing on the connection between the failed deals and the push for leadership change. Meanwhile, Barron's has raised questions regarding whether more pain is on the way for the pharmaceutical giant, reflecting a general sense of instability surrounding the company's current trajectory. To understand why this is trending, it is necessary to look at the sequence of failures involving the company's pipeline. The failure of the late-stage DM1 study for Del-desiran serves as a concrete example of the trial setbacks that have triggered investor alarm.
The context provided by Reuters suggests that these are not isolated incidents but part of a pattern of costly deal setbacks that have now led a significant investor to challenge the current governance of the company. The intersection of clinical failure and financial loss has turned the spotlight directly onto the board's decision-making processes and its approach to M&A. Looking ahead, the market will be watching for the official response from the Novartis board regarding the call for an overhaul. Further developments will likely center on the fallout from the Del-desiran study failure and how the company intends to address the triple asset stumble mentioned by BioSpace. Investors will likely monitor whether other major shareholders join the call for a shake-up or if the company announces changes to its leadership or M&A strategy to stabilize the share price and restore confidence in its drug development pipeline.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 65d ago.
Quick answers
Why is a Novartis shareholder calling for a board overhaul?
The call for a board shake-up follows a series of costly deal setbacks and failures in drug trials.
Which specific drug trial failed?
Del-desiran failed its late-stage DM1 study, which led to a fall in Novartis shares.
What has BioSpace reported regarding Novartis?
BioSpace reported that a triple asset stumble by Novartis is dragging down its peers.
Coverage (7)
- Novartis: More Pain on the Way? Barron's · 68d ago
- Novartis drags peers down with triple asset stumble BioSpace · 68d ago
- Major shareholder calls for board change at Novartis: report FirstWord PHARMA · 68d ago
- Novartis investors turn spotlight on M&A after trial setbacks Reuters · 68d ago
- Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall Yahoo Finance · 68d ago
- EXCLUSIVE: Major Novartis shareholder calls for board shake-up after drug trial setbacks Reuters · 68d ago
- Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters Fierce Pharma · 68d ago
Topics
Related trends
Nvidia rejects Jensen Huang’s offer to return as CEO despite pressure from Silicon Valley
AP News reports Nvidia's board rejected founder Jensen Huang's offer to return as CEO despite Silicon Valley pressure.
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Madison Huang, Jensen Huang’s Daughter, Became a Powerful Force at Nvidia
Coverage from The New York Times and Chosun Ilbo reveals Jensen Huang's daughter Madison has become an influential unofficial force at Nvidia, prompting internal leadership scrutiny.
These Companies Are Using Trump’s Tariff Refunds for Executive Bonuses
Major retail and technology corporations are reportedly directing federal tariff refunds toward executive bonuses instead of consumer refunds.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.